Trials / Terminated
TerminatedNCT00059644
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM for the Treatment of Critical Leg Ischemia
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 560 (planned)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ecraprost in lipid emulsion |
Timeline
- Start date
- 2001-07-01
- Completion
- 2004-06-01
- First posted
- 2003-05-02
- Last updated
- 2005-06-24
Locations
27 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00059644. Inclusion in this directory is not an endorsement.